Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MGLL | Q99685 | 9/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923177 | 0.88 | MGLL (0.56) | MEN1CYP2D6KMT2AMGLLFAAH | |
| SCHEMBL3596868 | 0.84 | SRD5A2 (0.54) | MEN1KMT2AMGLLFAAH | |
| SCHEMBL5246296 | 0.83 | MEN1 (0.53) | MEN1CYP2D6KMT2AMGLLOPRD1 | |
| Hydrochloric Acid SCHEMBL5244276 | 0.81 | MEN1 (0.55) | MEN1CYP2D6KMT2AMGLLSLC6A2 | |
| SCHEMBL18203121 | 0.81 | MEN1 (0.67) | MEN1CYP2D6KMT2AMGLL | |
| SCHEMBL1582773 | 0.81 | KMT2A (0.96) | MEN1CYP2D6KMT2AMGLLHTT | |
| SCHEMBL654532 | 0.81 | MEN1 (0.67) | MEN1CYP2D6KMT2AMGLL | |
| Hydrochloric Acid SCHEMBL2366330 | 0.79 | KMT2A (1.00) | MEN1CYP2D6KMT2AMGLLHTT | |
| Hydrochloric Acid SCHEMBL229430 | 0.79 | MEN1 (0.70) | MEN1CYP2D6KMT2AMGLL | |
| Bromide SCHEMBL10968871 | 0.79 | KMT2A (0.93) | MEN1CYP2D6KMT2AMGLLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-06-02 | — | — | US | disclosed |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| EP-1323716-B1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | TAKEDA PHARMACEUTICAL (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-7008950-B1 | Benzofurans as suppressors of neurodegeneration | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-07 | — | — | US | disclosed |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1323716-A1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | Takeda Chemical Industries, Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-0988289-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998055454-A2 | BENZOFURANS AND BENZOTHOPHENES AS SUPPRESSORS OF NEURODEGENERATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-10 | — | — | WO | disclosed |
| US-5021428-A | Novel chemical compounds for the prophylactic treatment of migraine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-06-04 | — | — | US | disclosed |
| US-4912117-A | Therapy for varient angina | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0208235-B1 | N-ARALKYL PIPERIDINEMETHANOL DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0208235-A1 | N-Aralkyl piperidinemethanol derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | NES, MKI67, CCNO | MEN1 2906/4885CYP2D6 3345/4885KMT2A 1061/4885 |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | MEN1 326/4885CYP2D6 2748/4885KMT2A 2106/4885 |
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, VHL | MEN1 419/4885CYP2D6 1100/4885KMT2A 2073/4885 |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | NES, HAT1, PROX1 | MEN1 3718/4885CYP2D6 2785/4885KMT2A 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.